Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 7Genitourinary 3Endocrine 3Breast 3Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 10Small Cell Lung Carcinoma 6Thymoma 5Carcinoma, Renal Cell 4Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Gastrointestinal Stromal Tumors 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thoracic Neoplasms 1Somatostatinoma 1Recurrence 1Rectal Neoplasms 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nervous System Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma 1

Interventions

pembrolizumab 4Magnetic Resonance Spectroscopy 4trametinib 3selpercatinib 3Trastuzumab 3ulixertinib 2larotrectinib 2binimetinib 2belinostat 2alectinib 2Sunitinib 2Specimen Handling 2Radiotherapy 2Paclitaxel 2Nivolumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Biopsy 2130-nm albumin-bound paclitaxel 2vandetanib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Sunitinib × Thoracic × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡